BioCryst Pharmaceuticals, Inc. (BCRX) Earnings Call Transcript
August 5, 2026
Earnings Call Speaker Segments
Good morning, and thank you for joining BioCryst's conference call covering our corporate update and financial results for the second quarter of 2026. With me on the line today are Charlie Gayer, our President and Chief Executive Officer, Dr. Sandeep Menon, our Chief R&D Officer, and Babar Ghias, our Chief Financial Officer. You can find a press release and a slide presentation covering today's news on our investor relations website. This call includes forward-looking statements, among them statements about future results, unaudited and forward-looking financial information, and the company's future performance and/or achievements. Known and unknown risks and uncertainties apply to these statements, and those risks could cause our actual results, performance, or achievements to differ materially from any future results or performance expressed or implied in this presentation. For more information, including a detailed discussion of these risks, please see slide two of the presentation. Today's conference call also includes non-GAAP financial measures. To see a reconciliation of these measures against the most directly comparable GAAP financial measure, please refer to the earnings press release available on our investor relations website. I'll now hand the call over to Charlie Gayer.
Thank you, Nick Wilder. Moving into the second quarter, our execution stayed strong across both the commercial side and development efforts; the Astria Therapeutics integration is now finished, and we pushed cash generation even higher by growing revenue while keeping spending disciplined. That improvement in cash flow—reinforced by the strategic choice to shut down our internal drug discovery work—will let us assemble a well-balanced pipeline of rare disease assets via external innovation, as Sandeep Menon and Babar Ghias are going to explain. Sandeep Menon will additionally share further detail on navenibart, for which we finished enrolling the biggest blinded HAE trial ever conducted, and we did so ahead of the planned timeline. Enrollment is also going well for our BCX17725 proof of concept trial in Netherton syndrome, and we anticipate data before this year ends. There's exciting news this week for HAE families too, since ORLADEYO oral pellets have begun shipping to children. Even with the manufacturing delay, we've gotten 47 prescriptions for ORLADEYO pellets as of July 31st, far exceeding what we projected for the entirety of 2026. Prior authorizations are finished for roughly 50% of these patients. The approval rate has been robust so far. There's much for us to learn regarding ongoing prescription rates of paid therapy, plus real-world outcomes among kids on ORLADEYO. Delivering this greatly needed therapy is something we're thrilled about. Our Q2 market research revealed that both patients and physicians reported higher preference for and satisfaction with ORLADEYO versus a year earlier. Market demand reflected this, with new prescriptions for ORLADEYO capsules in Q2 matching our history and expectations; we also brought on new prescribers at a pace consistent with historical trends. Turning to payers, the busiest stretch of reauthorization season has passed. We keep achieving incremental gains in the paid rate, which closed the quarter at 84%, up from 83% a year before. Last, we're happy to be working with CareMed as our new sole source pharmacy for ORLADEYO shipments to patients. Since launch, the sole source model has served as a cornerstone of our strategy. Given that our HAE portfolio and the patient count we serve keep expanding, we picked CareMed for their capacity to scale operations alongside our growth. Every ORLADEYO pellets prescription for kids ships from CareMed, and the 12 and up population will move over during this month. Serving these patients together is something we look forward to. I'll hand the call to Sandeep Menon to walk through our pipeline developments.
Appreciate that, Charlie Gayer. I'm happy to report that as of June, enrollment is now complete for our pivotal trial, ALPHA-ORBIT, studying navenibart — our investigational long-acting injectable plasma kallikrein inhibitor intended for HAE prophylaxis. This product's differentiated profile has us excited about its potential to reshape the injectable portion of the market. Top-line data from this program are expected to be announced during the third quarter of 2027. Since navenibart's extended dosing schedule involves administration every six months, we intend to keep the trial blinded so we can gather one year of safety and efficacy data, as the FDA agreed, which places us in a unique position to assess efficacy at six and 12 months. I also want to speak to our June choice to shut down internal discovery programs and close the research unit in Birmingham. From the time I came to BioCryst, we've carried out a comprehensive review of our programs, capabilities, and strategic options to make sure we're positioned for future success. Following careful consideration, our team determined that broadening our access to external innovation is the optimal way to allocate resources and speed development of a stronger pipeline. This choice doesn't affect our clinical programs, including BCX17725, which stays on track for early clinical data in patients from part IV of our phase Ib study by the end of this year. We're still excited about the potential to bring forward a treatment for patients with Netherton syndrome, a rare, severe skin condition that has no approved therapies; we'll keep actively searching for external assets. Ending internal research widens our scope to build a balanced pipeline of differentiated assets across clinical stages in areas of high unmet need where our scientific, clinical, and commercial strengths can be leveraged. I'll now hand things over to my colleague, Babar Ghias.
Thank you, Sandeep Menon. During our second fiscal quarter, we saw ongoing momentum throughout the business, consistent expansion for ORLADEYO, meaningful strides in our clinical pipeline—as you've just heard—and, crucially, important progress toward fixing the manufacturing problem so that our pediatric launch can move ahead. This quarter also once again demonstrated our financial strength, with robust operating profitability and a cash position that keeps our balance sheet in great shape for carrying out our go-forward strategy. In what I say today, I'll reference certain non-GAAP figures, which are adjusted for revenues and expenses tied to our former European ORLADEYO business, stock-based comp, and costs connected to the Astria acquisition. Further information on adjustments and reconciliations is available in the press release. We hold the view that non-GAAP figures give a clearer underlying picture of our business looking ahead. Having said that, let me move to the financial results. Total revenue for the second quarter of 2026 rose 45% year-on-year on a comparable basis. That excludes the European divestiture. I'd point you to ORLADEYO revenue of $158.2 million for the quarter, up 10% year-on-year on that same comparable basis. Demand from new patients continues to be strong, and as we deepen our grasp of ped-market dynamics through real-world outcomes, we are confident it will keep adding to our growth. Findings from market research remain just as consistent when it comes to the value of ORLADEYO, and naturally that shows up in how we execute commercially day to day. We are still bringing on new prescribers, and we observe long-term patient retention that aligns with past trends. Now that the reauthorization season is mostly behind us, we achieved a modest uptick in our paid rate versus last year, which matters and is impressive at the same time, since you may remember we had already delivered a significant gain on that metric a year ago. That genuinely reflects how much HAE patients benefit from ORLADEYO. Our quarterly total revenue also includes $55.7 million recognized in the quarter from the upfront payment under our navenibart European license agreement with Neopharmed Gentili. I'm also delighted to report that operating costs across our business are holding steady. As our press release shows, our non-GAAP G&A and sales and marketing expense categories stayed relatively flat for both the three-month and the six-month period versus prior periods. The rise in R&D stems from ongoing phase III work for navenibart, which is what you'd expect. Given these trends, we recorded a strong non-GAAP operating profit of $113.2 million for the quarter. Importantly, we have deliberately acted to further sharpen our cost structure going forward. As we said in our June news release, we are moving our R&D strategy toward an external innovation model, ending our internal discovery programs, together with the previously announced shutdown of our Birmingham facility by the end of this year. What we have now is a tighter, more targeted operating structure, and we expect it to deliver substantial savings on the cost side as our older R&D spending keeps declining. That already let us lift our non-GAAP operating cost outlook for the rest of the year, taking it from the prior $454 million-$470 million band down to $420 million-$440 million. Our balance sheet keeps benefiting from this kind of financial rigor. Cash equivalents and investments stood at a bit above $350 million when the quarter closed. And notably, we produced positive cash flow during the quarter even if you exclude the upfront money from the license agreement. In short, the balance sheet has never looked stronger; with that said, let me turn to how we're thinking about our strategy financially from here. Our business keeps throwing off solid profitability and growing cash flow. Two catalysts matter a great deal to us, and one of them boosts our growth trajectory in the near term. When it comes to BD, we see no reason to put unnecessary strain on our balance sheet. As Sandeep Menon mentioned before, moving toward external innovation lets us assemble a more balanced pipeline of clinical assets spanning every stage. These may be early to mid-stage clinical programs, where the flexibility around deal structure will be far greater. In the end, what matters to us isn't how many clinical programs we have but how good they are, since they feed our overall growth profile. Compared with other companies our size, we sit in a truly distinctive spot: we can fund BD and R&D, turn out profitable growth with cash flow to spare, and stay flexible enough to consider paying down balance sheet debt and/or repurchasing shares. Now for financial guidance. Because the navenibart EU license has closed, we are lifting our total revenue guidance to $690 million-$715 million. Even with the pediatric launch pushed back, we believe ORLADEYO's long-term trajectory remains solid, so we are keeping our full-year 2026 ORLADEYO revenue guidance at $625 million-$645 million. For non-GAAP operating costs, the range stays at $420 million-$440 million, as we announced on June 29th. Our business has been through several pivotal transactions over the past 12 months. The Europe sale, then the Astria acquisition, a CEO transition, and most recently the Birmingham decision. While the new BioCryst, I'd say, is still evolving, one constant has been a strong track record of operating performance all along. For that, I'm deeply thankful to our team for staying laser-focused on what matters most, pushing ORLADEYO and our pipeline forward to bring critical, life-changing medicines to patients; with that, operator, we're ready to take questions.
Morning, and thanks so much for fielding the questions. I've got just a couple. First, ORLADEYO seems to have posted a really strong quarter. One of your rivals, as I understand it, said their prophylactic offering was picking up switches across a variety of patients. So I'm wondering — maybe Charlie Gayer, or whoever wants to weigh in — whether you've got any anecdotal sense of how ORLADEYO held up in terms of persistence during that stretch? Is competitive pressure building? Second, on the Netherton program: I believe you said enrollment is moving along. Are you getting close to finishing recruitment? I'd be curious to hear more about any hurdles or lessons so far. Thanks so much.
Great. Thanks, Laura Chico. I'll handle the first one. Sandeep Menon can speak to the second, on Netherton. Clearly there are new rivals in the market, new injectables, and what we're observing matches what all our market research predicted — the injectables are mostly taking share from existing injectables, especially TAKHZYRO. Retention for ORLADEYO overall follows the same pattern Babar Ghias described in his statement. Naturally, some patients do leave us, and these days we tend to lose them to the newer products rather than the older ones, which is precisely what we anticipated. As for ORLADEYO's growth overall, we feel very positive. Sandeep Menon, would you like to cover the Nethertons?
Appreciate that question. Our proof-of-concept data remains on schedule to arrive at the close of this year. What observations do we have? In the healthy volunteer results you've already reviewed, tolerability from a safety standpoint has held up well, and where the drug distributes is within the portion of the epidermis housing all the activity. Right now, that's all we're in a position to address. Additional information still needs to arrive before we can fully grasp the PK/PD picture alongside the clinical efficacy endpoints.
Laura Chico, on the question of how many participants are enrolling in the trial: enrollment has continued at a steady rate, and we're confident that we will get to 12 patients by the end of the year, and that is going to determine our next steps for the program, which is backed by $450 million.
Yeah.
Great, thank you all.
Hi everyone, I appreciate you fielding this. To build on what was discussed regarding Netherton, what sort of performance do you anticipate from a placebo group? Certain SPEVIGO results indicate some degree of gain relative to baseline. Meanwhile, the Daiichi findings pointed to what might be a slight worsening under placebo. So I'm wondering how you reconcile these pieces and frame what counts as a favorable efficacy outcome. Thanks.
Yeah, regarding BCX17725, we see it as potentially the very first targeted therapy given systemically to treat Netherton syndrome. Everything else that's been used, all the other modalities, none of them hit the specific target that's truly required in Netherton syndrome. That target is KLK5, and that's the one we go after. When we consider these patients, there's nothing approved for them. Based on what we've heard from patients and KOLs, any improvement in signs and symptoms for Netherton patients would represent a major step forward. That's what we continue to learn, and by the end of the year, we'll have a clearer picture of the full dataset. Of course, there will be some placebo response. The disease itself naturally fluctuates, waxing and waning. Overall, it's a highly variable condition.
That sounds fine. Thank you.
Hi everyone. We appreciate you answering our questions; we have two. To start, when we consider ORLADEYO, could you perhaps walk us through how many clinicians were added in this quarter compared with what's typical historically? With the pediatric launch, what sort of halo effect do you anticipate? I hear what you're saying regarding the injectable and its share among new patients. Just give us a sense of how ORLADEYO has kept moving forward at a steady pace. That's the first one. Second, could you discuss the new specialty pharmacy arrangement? Is there any expectation to set around this transition? Will it truly go smoothly? Help us understand the timing of the U.S. launch for ORLADEYO, and perhaps what the back half could look like compared with the opening two quarters. That's my second question. One very brief follow-up about Netherton. Since you're now in part four, is there anything preliminary you'd be willing to say regarding part three? Many thanks.
Okay. Thank you, Stacy Ku. Regarding the additions of clinicians, you may remember that previously we mentioned roughly 60 new doctors each month writing prescriptions for ORLADEYO. We came in slightly higher than that figure. ORLADEYO keeps building momentum in the market. As for the pediatric halo, it's clearly still early, yet among those 47 prescriptions, several came from doctors who hadn't previously written for ORLADEYO. That's an encouraging early indicator. As I said, there's much to learn about pediatrics now that we have product in the market, but we've gotten off to a very strong start. On the new SP transition to CareMed, the key decision, as I noted, was their capacity to grow alongside us as we expand. During that process, we also examined their experience onboarding active programs, and CareMed brings substantial experience in that area, and their track record has impressed us. Whenever a switch like this happens, bumps are possible; this entire switch is only beginning this month. We don't anticipate it will impact ORLADEYO over the long term, but we'll simply have to watch how the quarter unfolds. We believe over the long term, this will be excellent for patients. Our guidance, as Babar mentioned, remains unchanged, $625 million-$645 million for the year. I don't even have to hand this to Sandeep Menon to say anything about Part Three. No, there were too few patients, too short a time. We're very happy with how Part Four is enrolling, and we look forward to having data at the end of the year.
Thanks a lot.
Thanks; Timur Ivanov here, filling in for Steven Seedhouse. We've got a question about ORLADEYO. Could you give us some detail on how much volume expanded during the quarter? It sounds like revenue was up 10% compared with a year earlier, yet a 9% price hike also occurred. You brought up an improved paid rate. So what would that suggest regarding year-over-year volume growth for the quarter? Thanks.
Yeah, absolutely, Timur Ivanov; it's roughly an even split. You may remember that with the 9% price increase, we said before that we retain about 4.5% of it — clearly we did a little better on the paid rate. On the whole, it came to around half from volume, half from price and reimbursement, more or less.
Great. Thank you.
Hi, Sylvia here, filling in for Jess Fye. We've got two questions. Could you give us more detail about what your priorities are for business development? Is this more about bolt-on acquisitions for the clinical pipeline, or partnerships, and what sort of profile businesses would that involve? My second question is whether you can walk us through the OpEx outlook for 2027 and beyond under the scenario where Netherton moves forward and the one where it doesn't, just so we can understand the flex factors there. Thank you.
Yeah. From a BD standpoint, I'd say the goal is building a pipeline of really high value, with validated biology and proof of principle. As I said, obviously we won't put stress on our balance sheet, so large company acquisitions that would create stress aren't something we're considering. We're extremely focused on delivering on our catalyst; these could be clinical mid-stage assets, with an emphasis on clinical assets. That's where we believe we can make a real impact. That's how we think about the world from a BD perspective. As I said, we generate cash and are self-sufficient, so large capital raises to fund our BD or R&D operations aren't necessarily something we're looking at. From an OpEx standpoint, I think the outlook is really strong; we haven't actually given 2027 guidance, but as you may remember, when we lowered our guidance, that was midway through the year when we were making this decision. When we're ready to provide that guidance, we anticipate that costs will keep going down because we'll be past the Birmingham facility closure. We'll be past closing our internal programs. Looking ahead, it's basically Netherton and navenibart expenses. As you can imagine, the navenibart expenses will be coming down as well as that program reaches its completion. Going forward, the operating expense guidance, absent any new BD deals, will be really strong. That said, it's our objective that even as we bring BD assets in, BioCryst is committed to delivering profitable growth. That is a key imperative for us to remain profitable and cash flow positive.
Hello, and good morning. I appreciate you taking my questions. The first one is about the pediatric launch. Charlie Gayer, I believe you said the early figures were coming in above what you had anticipated. I'm just wondering whether that shifts your view of that opportunity, and if we ought to expect the paid Rx rates — which I believe sit at roughly 80% at present — to look comparable on the pediatric side. Then my second question: looking at slide six, where you point out that 1,600 patients are on therapy right now and 3,500 others have tried the product since it launched. My assumption is that somewhere between 3,000 and 4,000 patients have still not tried ORLADEYO as of yet. Since you managed to reach these other patients through your existing prescriber base, will you have to go beyond the 1,500 unique prescribers you have today?
Yes. Thank you, Serge Belanger. On the pediatrics front, as I mentioned, the early demand has us encouraged, given that we only began shipping product out to patients this week, and clearly that ought to make prescribers feel more at ease as well; we need to sort of watch how the trend develops. Calling it is a bit premature, though the early signals are definitely quite positive. On the paid rate, our expectation is that it will be at minimum within the range seen for capsules. The payer mix is going to differ somewhat, naturally, since Medicare won't be part of it — it will really break down between commercial and Medicaid. The early indicators on that front look good too, and the pediatric pellets fit directly into the contracts we already hold. Getting these products onto formulary isn't some new lift. Regarding the opportunity going forward, the fact that demand has stayed as steady and robust as it has across the past couple of years, along with our addition of new prescribers, simply demonstrates that ample opportunity remains, and our market research confirms that as well. We likewise observe that new prescriptions are arriving quite strongly from prescribers we already have, as well as, clearly, from these new prescribers who are coming on board. That pattern has genuinely not shifted, and pediatrics can only add to that.
Morning, and thanks for taking my questions. I have two. First, regarding navenibart, with enrollment finished and the study expanded, I'm curious whether that expansion came from interest being greater than anticipated or from anything you observed about dropouts? Also, what kinds of patients are being enrolled, and does this affect statistical powering? Should we think of this as almost all adults, with only a small number of adolescents? Second, with ORLADEYO, it appears you've reached a stable position on keeping patients on therapy. I'm wondering whether there are further ways to strengthen that before a possible rival product arrives. Is there anything in forthcoming oral prophylaxis data from competitors that might cause you to change your approach, given the possibility of another entrant? Thank you.
Sure, Brian Abrahams. We'll cover navenibart — I'll handle the first portion, and Sandeep Menon, you can address the second. On the expansion, it wasn't related at all to statistical powering. It was entirely driven by interest from patients and investigators. As we said, this was the biggest blinded study ever conducted in HAE, and even so it recruited at the same speed as other recent, smaller trials; so I believe that speaks to the team, excuse me, and to the product's profile. Would you like to discuss the powering overall?
Right. On the powering side, we're already overpowered for this trial, so there's nothing that worries us there. What happened here really just came down to investigators showing greater interest. And honestly, that's a really strong signal for everyone involved, in terms of how much uptake there is and how much value physicians see in this type of modality along with the dosing regimen.
When it comes to keeping patients on therapy, one area we constantly examine is our own operations and the results we're delivering. We believe there's room to make additional gains in a few spots, though the overall retention figure leaves us satisfied. The explanation is really the same one we gave earlier: either a patient responds very well to ORLADEYO and stays on it consistently, or they don't and they go elsewhere. Both our market research and our real-world evidence support this, and we anticipate it will remain the case. One item we'll be monitoring involves the pediatric indication — what will retention look like in that group? Getting a genuine real-world read on that will require several quarters. In the APEX-P clinical trial, long-term retention of patients at 1 year and 2 years came in higher than the numbers from our adult APEX-2 trial. Whether that pattern holds in the real world remains to be seen.
That is quite useful. Many thanks.
Hello, good morning. Congratulations on the quarter, and I appreciate you fielding my questions. Regarding the momentum in new patient prescriptions that held steady during the second quarter, is it solely from new pediatric patients or prescriptions, or could you give additional detail on how we might measure this and grasp the share coming from new adult patients as opposed to pediatric patients?
Certainly. Yes, demand for ORLADEYO capsules among the 12 and up population was highly consistent with what we have observed across the past couple of years. That matched our expectations, yet it was also wonderful to witness that ongoing steady and robust demand. The pediatrics have gotten off to a fantastic start, which is purely additional upside, and we will monitor how that develops through the next few quarters.
Understood. All right, I just want to make sure — regarding that 84% paid rate, is it solely the adult population that's counted? I'd like to hear your thoughts on how much further that paid rate might climb across the third and fourth quarters.
Yes, adults are the only group in that figure, since the pediatrics and the pellets weren't available yet during Q2. Keep in mind as well that among those patients, some have no insurance at all — roughly 4% out of the 16% receiving free product. In our view, solid headway is being made and we keep narrowing the gap. Our target over the long haul was 85%, and I've always maintained that once we reach 85%, the bar will be raised again, and our confidence is high. As I've mentioned previously, it's typical during the back half of the year for the paid rate to soften somewhat, since the mix shifts toward newly arriving patients, who usually don't reach that 84% level as fast. For a portion of them, more time is needed. The usual trend is a loss of 1% or 2% across the latter six months, which we then recover during next year's reauthorization season. The close of Q2 strikes me as an excellent moment to gauge how things are going, which is the reason we highlighted it this year, given that we improved by 1% compared with last year. Looking ahead to next year, my expectation is that we'll be at or above the level we saw at the close of Q2 this year.
Understood, that's useful. I appreciate you answering my questions.
Hi, thanks for fielding the question. Speaking of the pediatric chance here, you've mentioned previously around 500 patients who've been diagnosed, and 10% of them are already pursuing prescriptions. Could you share a bit about that initial pattern — are families approaching you asking about ORLADEYO, or is it your team going out into the community? What's your thinking on the trajectory, plus the diagnosed group as you engage more and spread the word?
Yes, once more, Jonathan Wolleben, what we've observed is genuinely thrilling. As you noted, it's near 10% out of that 500 figure. Our market research shows us that doctors are, first, quite eager to prescribe ORLADEYO pellets for children, and second, having an oral Prophy option leads them to consider prescribing for a larger share of their pediatric patients overall. Early indicators suggest we might not just shift additional existing Prophy patients to oral Prophy, but also enlarge the market, broaden the market. There ought to be closer to 1,200 children diagnosed within this age group. We'll be monitoring for evidence that the 500 figure increases. Initial signals look good, though we'll require several more quarters to truly understand how this unfolds.
Should we expect pediatric prescription figures to keep coming our way in future updates?
I don't anticipate sharing that precise figure with you in the future. What we'll provide is a broad sense of how demand is trending overall, and we'll likely describe which way pediatric demand is heading. You made the right call there — it accounts for nearly 10% of that 500 figure; we felt it mattered enough to mention right now, but going forward, we probably won't hand over the numeric value.
Got it. Thanks, Charlie Gayer.
Appreciate it. The queue is empty now. Everyone, we're grateful you joined us. That wraps up what we had scheduled for today, so you're free to leave the call at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete BioCryst Pharmaceuticals, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to BioCryst Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.